CD19 and acute lymphoblastic leukemia: The ability of K12 CAR-T cells to treat T-ALL in vivo was evaluated in sub-lethally irradiated NSG mice by intravenously injecting Jurkat cells expressing firefly luciferase followed by treatment with K12 CAR-T cells, CD19 CAR-T cells, or vehicle control (Figure 4A).